Abstract：
Rhipicephalus microplus, known as the hard tick, is a vector for the parasites Babesia spp. and Anaplasma marginale, both of which can cause significant financial losses to the livestock industry. There is currently no effective vaccine for R. microplus tick infestations, despite the identification of numerous prospective tick vaccine candidates. As a result, the current research set out to develop an immunoinformatics-based strategy using existing methods for designing a multi-epitope based vaccination that is not only effective but also safe and capable of eliciting cellular and humoral immune responses. First, R. microplus proteins Bm86, Subolesin, and Bm95 were used to anticipate and link B and T-cell epitopes (HTL and CTL) to one another. Antigenicity testing, allergenicity assessment, and toxicity screening were just a few of the many immunoinformatics techniques used to identify potent epitopes. Multi-epitope vaccine design was chosen based on the antigenic score 0.935 that is promising vaccine candidate. Molecular docking was used to determine the nature of the interaction between TLR2 and the vaccine construct. Finally, molecular dynamic simulation was used to assess the stability and compactness of the resulting vaccination based on docking scores. The developed vaccine was shown to be stable, have immunogenic qualities, be soluble, and to have high expression by in silico cloning. These findings suggest that experimental investigation of the multi-epitope based vaccine designed in the current study will produce achievable vaccine candidates against R. microplus ticks, enabling more effective control of infestations.
摘要：
微小根皮phalus，被称为硬蜱，是寄生虫巴贝斯虫的载体。和边缘无理虫，这两者都可能给畜牧业造成巨大的经济损失。目前尚无有效的R.microplus蜱感染疫苗，尽管确定了许多潜在的蜱疫苗候选物。因此,当前的研究开始开发一种基于免疫信息学的策略，使用现有的方法来设计一种基于多表位的疫苗接种，该疫苗不仅有效，而且安全，并且能够引起细胞和体液免疫应答。首先,R.microplus蛋白Bm86，Subolesin，和Bm95用于预测和连接B和T细胞表位(HTL和CTL)彼此。抗原性测试,变应原性评估,和毒性筛选只是许多用于鉴定有效表位的免疫信息学技术中的一小部分。基于抗原性评分0.935选择多表位疫苗设计,所述抗原性评分是有希望的疫苗候选物。分子对接用于确定TLR2和疫苗构建体之间相互作用的性质。最后,分子动力学模拟用于评估基于对接评分的疫苗接种的稳定性和紧密度。开发的疫苗被证明是稳定的，具有免疫原性，可溶，并通过计算机克隆具有高表达。这些发现表明，本研究中设计的基于多表位的疫苗的实验研究将产生针对R.microplus蜱的可实现的疫苗候选物，能够更有效地控制感染。
